# A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS

> **NCT05788679** · PHASE2 · RECRUITING · sponsor: **Karolinska University Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Myelodysplastic Syndromes
- Acute Myeloid Leukemia With Myelodysplasia Related Disease and < 30% Blasts
- Mixed Myelodysplastic/Myeloproliferative Disease

## Interventions

- **DRUG:** Azacitidine
- **OTHER:** Donor lymphocytes
- **OTHER:** Tapering of immune suppression

## Key facts

- **NCT ID:** NCT05788679
- **Lead sponsor:** Karolinska University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-22
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05788679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05788679, "A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05788679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*